Just months after its Nasdaq debut in June, Meiragtx Holdings plc put its relatively new shares to work in an all-stock-based acquisition of Vector Neurosciences Inc. Announced in October, the transaction brought the London and New York-based company an adeno-associated virus (AAV) encoding glutamic acid decarboxylase (AAV-GAD) gene therapy candidate poised for continued phase II development in Parkinson's disease. Now the company has five ongoing clinical programs in eye, salivary gland and central nervous system disorders, advancing alongside a pipeline of preclinical and research programs and is further extending its ambitions.